PLGA-Based Dual Drug Delivery and Targeted Nanoparticle Systems for Enhanced Breast Cancer Therapy

Abstract

A major source of concern is the growing global concern regarding cancer, a disease that has attracted the attention of scientists in recent decades. Breast cancer is the most common type of cancer that affects women worldwide and is caused by cells in the breast. Breast cancer accounted for 25% of all cancer diagnoses in 2012. The process of metastasis begins with the invasion of adjacent organs and continues with the dissemination of lymph nodes, invasion of blood vessels, and the spread of cancer to other parts of the body. Hormone therapy, radiation therapy, chemotherapy, poly-chemotherapy, and surgical removal of cancerous tissue are the current options for treating breast cancer.PLGA-based nanoparticles have the potential to enhance treatment efficacy. In comparison to other polymers, nanoparticles derived from PLGA are well-suited for clinical trials.

This is because PLGA has been approved for use in a variety of drug delivery systems by both the FDA and the EMA. Biomedical research into drug delivery with PLGA or polymers derived from PLGA has many promising avenues for maximizing therapeutic (antitumor) efficacy while minimizing adverse effects.